Insmed Inc. (INSM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$126.29-0.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INSM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -16.8% |
| Our one-year growth estimate | diamond | 100.0% |
Growth built into the price is above our model estimate.
The price assumes 116.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers
INSM — litigation filed
Dated 2026-04-07
Other Events. On April 7, 2026 , the Company issued a press release announcing topline efficacy and safety results from its Phase 2b CEDAR study of brensocatib in patients with HS. The CEDAR study was a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of brensocatib in adults with moderate to severe HS. The study enrolled 214 patients at 72 sites globally. In the study, participants were randomized 1:1:1 to receive brensocatib 10 mg, brensocatib 40 mg, or…
Why it matters: Progress on INS1148 is crucial for expanding the product pipeline. Delays could hurt future growth.
Watch forThere was an announcement of good trial results or a partnership for INS1148.
Also watch forThere was an announcement of delays or problems in INS1148 development.
Why it matters: A good choice can help BRINSUPRI grow. It can also help them expand to other countries.
Supportive ifJapan will approve BRINSUPRI in the second half of 2026.
Worry ifThe decision on BRINSUPRI in Japan is delayed past 2026.
Why it matters: This revenue shows that ARIKAYCE is still accepted in the market. It shows good sales strategies.
Supportive ifARIKAYCE made over $116.3 million in revenue for Q3 2026. This shows steady growth.
Worry ifARIKAYCE revenue for Q3 2026 falls below $450 million.
Why it matters: If healthcare revenue growth speeds up, it could benefit Insmed's performance.
Supportive ifHealthcare revenue growth increases back toward 10% or higher.
Worry ifHealthcare revenue growth keeps slowing down. It is now below 10%.
Why it matters: Results from the CEDAR study will impact the outlook for brensocatib.
Worry ifGood results from the CEDAR study are announced.
Less concerning ifNegative results or delays in the CEDAR study are reported.
Why it matters: Good results from the PALM-PAH study could raise confidence in TPIP's market chance.
Watch forPALM-PAH study shows significant improvement in 6MWD at the 24-week mark.
Also watch forPALM-PAH study data shows no big change in 6MWD.
Why it matters: Filing an IND for INS1148 could show progress in the company's work on respiratory diseases.
Supportive ifInsmed files an IND for INS1148 in the second half of 2026.
Worry ifNo IND filing for INS1148 occurs in the second half of 2026.
Why it matters: Earnings results can change how investors feel. They also show trends in revenue.
Watch forEarnings were better than expected. There is good guidance for future quarters.
Also watch forEarnings were worse than expected. Management has lowered guidance for the future.
Why it matters: BRINSUPRI is growing revenue fast. This supports the higher guidance and market demand.
Supportive ifBRINSUPRI revenue growth exceeds 40% year over year in Q3 2026.
Worry ifBRINSUPRI revenue growth falls below 30% year over year in Q3 2026.
Why it matters: A good decision could increase ARIKAYCE sales. It would also support the company's growth plan.
Supportive ifFDA approval for ARIKAYCE label expansion in Q4 2026.
Worry ifFDA denies the label expansion for ARIKAYCE in Q4 2026.
Why it matters: Good data from the TPIP trial could raise its market potential. It may also boost investor confidence.
Supportive ifPositive data reported from the Phase 3 PALM-PAH trial of TPIP in Q3 2026.
Worry ifNegative data reported from the Phase 3 PALM-PAH trial of TPIP in Q3 2026.
Why it matters: A good decision could open a big market for Insmed's main product.
Supportive ifApproval granted for brensocatib for NCFB in Japan in late 2026.
Worry ifBrensocatib may face delays or denials for approval in Japan.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$170 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $440 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,654 loss on $10,000 · 56.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.